Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

THANK YOU, DEW -

28 August:

Enanta resumed with a Buy at Roth Capital 16:19 ENTA Roth Capital analyst Zegbeh Jallah resumed coverage of Enanta Pharmaceuticals with a Buy rating and $104 price target. The current stock price is largely reflective of the company's hepatitis C virus revenue stream and its cash position of $435M, thus leaving its clinical pipeline of potential blockbusters undervalued, Jallah tells investors in a research note. Enanta has a "very potent" hepatitis B virus core inhibitor, EDP-514, in Phase 2 studies with data expected in the first half of 2021, notes the analyst.

Read more at:
https://thefly.com/n.php?id=3152704